Technology ID
TAB-4951
Inhibitors of HIV-1 Entry: Targeting the Phe43 Cavity of gp120
E-Numbers
E-145-2015-0
Lead Inventor
Debnath, Asim
Lead IC
NIAID
Co-Inventors
Curreli, Francesca
Kwong, Peter
Kwon, Young Do
ICs
NIAID
Applications
Vaccines
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Research Products
Computational models/software
The discovery involves the development of substituted phenylpyrrolecarboxamides as therapeutic agents for HIV-1 infection. These compounds target the Phe43 cavity of the HIV-1 gp120 protein, disrupting the interaction between gp120 and host cell receptors CD4 and CCR5/CXCR4, thereby inhibiting viral entry into host cells. This targeted approach presents a novel strategy for HIV therapy and prophylaxis, distinct from current treatments that target other stages of the viral life cycle. The discovery holds promise for the development of new drugs to combat HIV/AIDS, addressing a critical need for more effective and targeted antiviral therapies.
Commercial Applications
The discovery of substituted phenylpyrrolecarboxamides with therapeutic activity in HIV has broad potential applications in the field of antiviral therapy. These compounds could be developed into novel drugs for the treatment of HIV/AIDS, offering a targeted approach to inhibit viral entry into host cells. Additionally, these compounds may have applications in HIV prophylaxis, providing a new tool for preventing HIV infection in high-risk populations. Furthermore, the discovery of these compounds opens up possibilities for further research into the development of new classes of antiviral agents targeting other viral pathogens. Overall, the potential applications of these compounds extend beyond HIV therapy, paving the way for new approaches to combating viral infections.
Competitive Advantages
The substituted phenylpyrrolecarboxamides offer several competitive advantages over existing HIV therapies. Firstly, they target a specific site on the HIV-1 gp120 protein, the Phe43 cavity, which is crucial for viral entry into host cells. This targeted mechanism of action is distinct from current drugs, which target different stages of the viral life cycle. Additionally, the compounds have shown therapeutic activity in HIV-1, suggesting their potential efficacy in treating HIV/AIDS. Furthermore, by inhibiting viral entry, these compounds may also reduce the risk of viral resistance, a common challenge with current HIV therapies. Overall, the substituted phenylpyrrolecarboxamides represent a promising new approach to HIV therapy with the potential for improved efficacy and reduced risk of resistance compared to existing treatments.
Licensing Contact: